{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:24:48Z","timestamp":1792736688172,"version":"4.5.0"},"reference-count":84,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>OAS1(2\u2019-5\u2019-oligoadenylate synthetase 1) is a member of the Interferon-Stimulated Genes which plays an important role in the antiviral process. In recent years, the role of OAS1 in tumors has attracted attention, and it was found to be associated with prognosis in several tumors. However, the mechanism by which OAS1 affects tumors is unclear and pan-cancer study of OAS1 is necessary to better understand its implication in cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The expression, prognostic value, genetic alteration, alternative splicing events of OAS1 in pan-cancers were analyzed using TCGA, GTEx, HPA, GEPIA and OncoSplicing databases. OAS1 associated immune cell infiltration was evaluated using the ESTIMATE, xCell, CIBERSORT and QUANTISEQ algorithm. Single cell transcriptome data download using TISH database. Finally, the roles of the OAS1 on apoptosis, migration and invasion were investigated in two pancreatic cancer cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our results revealed significant differences in OAS1 expression among various tumors, which had prognostic implications. In addition, we investigated the impact of OAS1 on genomic stability, methylation status, and other factors across different types of cancer, and the effects of these factors on prognosis. Notably, our study also demonstrated that OAS1 overexpression can contribute to CTL dysfunction and macrophage M2 polarization. In addition, cell experiments showed that the knockdown of OAS1 could reduce the invasive ability and increased the apoptosis rate of PAAD cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These results confirmed that OAS1 could be a prognostic biomarker and therapeutic target for its potential role in CTL dysfunction and macrophage M2 polarization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1249731","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T02:24:00Z","timestamp":1697768640000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Multi-omics analysis reveals interferon-stimulated gene OAS1 as a prognostic and immunological biomarker in pan-cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Runyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12692","article-title":"Advances in the understanding of cancer immunotherapy","volume":"116","author":"Shore","year":"2015","journal-title":"BJU Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo3605","article-title":"Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment","volume":"14","author":"Kirchhammer","year":"2022","journal-title":"Sci Transl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"188930","DOI":"10.1016\/j.bbcan.2023.188930","article-title":"Time to abandon CAR-T monotherapy for solid tumors","volume":"1878","author":"Yin","year":"2023","journal-title":"Biochim Biophys Acta Rev cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200519060-00002","article-title":"Strategies of tumor immune evasion","volume":"19","author":"Seliger","year":"2005","journal-title":"BioDrugs Clin immunotherapeutics biopharmaceuticals Gene Ther"},{"key":"B10","doi-asserted-by":"publisher","first-page":"107969","DOI":"10.1016\/j.pharmthera.2021.107969","article-title":"Signal transducer and activator of transcription 3 signaling in tumor immune evasion","volume":"230","author":"Zhang","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B11","year":""},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"122101","DOI":"10.1016\/j.biomaterials.2023.122101","article-title":"Mechano-modulation of T cells for cancer immunotherapy","volume":"297","author":"Hyun","year":"2023","journal-title":"Biomaterials"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.xcrm.2023.100989","article-title":"T cell biomarkers come to the fore in cancer immunotherapy","volume":"4","author":"Sheriff","year":"2023","journal-title":"Cell Rep Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3109\/14017438609105917","article-title":"Thoracic injuries. A review of 93 cases","volume":"20","author":"Rasmussen","year":"1986","journal-title":"Scand J Thorac Cardiovasc Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.004","article-title":"Macrophages and cancer: from mechanisms to therapeutic implications","volume":"36","author":"Ostuni","year":"2015","journal-title":"Trends Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1102471","article-title":"The immune suppressive tumor microenvironment in multiple myeloma: The contribution of myeloid-derived suppressor cells","volume":"13","author":"Giannotta","year":"2022","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0617","article-title":"Myeloid-derived suppressor-cell dynamics control outcomes in the metastatic niche","volume":"11","author":"Kreger","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40364-021-00333-5","article-title":"Landscape of myeloid-derived suppressor cell in tumor immunotherapy","volume":"9","author":"Hao","year":"2021","journal-title":"biomark Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.12.8880","article-title":"RNase-L-dependent destabilization of interferon-induced mRNAs. A role for the 2-5A system in attenuation of the interferon response","volume":"275","author":"Li","year":"2000","journal-title":"J Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2021.2001373","article-title":"In silico modeling revealed new insights into the mechanism of action of enzyme 2'-5'-oligoadenylate synthetase in cattle","volume":"40","author":"Junghare","year":"2022","journal-title":"J Biomol Struct Dyn"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.07.005","article-title":"Functional evolution of the OAS1 viral sensor: Insights from old world primates","volume":"44","author":"Fish","year":"2016","journal-title":"Infect Genet Evol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0312-3","article-title":"Severe early-onset combined immunodeficiency due to heterozygous gain-of-function mutations in STAT1","volume":"36","author":"Baris","year":"2016","journal-title":"J Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nri888","article-title":"Viruses and interferon: a fight for supremacy","volume":"2","author":"Katze","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-71329-6_12","article-title":"The interferon-stimulated genes: targets of direct signaling by interferons, double-stranded RNA, and viruses","volume":"316","author":"Sen","year":"2007","journal-title":"Curr Top Microbiol Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/genes14020527","article-title":"Genetic ethnic differences in human 2'-5'-oligoadenylate synthetase and disease associations: A systematic review","volume":"14","author":"Gokul","year":"2023","journal-title":"Genes (Basel)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab337","article-title":"A genetic link between risk for Alzheimer's disease and severe COVID-19 outcomes via the OAS1 gene","volume":"144","author":"Magusali","year":"2021","journal-title":"Brain J neurol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/v12020152","article-title":"Characteristics of human OAS1 isoform proteins","volume":"12","author":"Di","year":"2020","journal-title":"Viruses"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00996-8","article-title":"Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19","volume":"54","author":"Huffman","year":"2022","journal-title":"Nat Genet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010464","article-title":"Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2 restriction factor","volume":"18","author":"Danziger","year":"2022","journal-title":"PloS Pathog"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abf9564","article-title":"Heterozygous OAS1 gain-of-function variants cause an autoinflammatory immunodeficiency","volume":"6","author":"Magg","year":"2021","journal-title":"Sci Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1025688","article-title":"Establishment and analysis of a disease risk prediction model for the systemic lupus erythematosus with random forest","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222370","article-title":"Interferon-alpha-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming","volume":"81","author":"Cooles","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1016\/j.jid.2022.02.018","article-title":"OAS1, OAS2, and OAS3 contribute to epidermal keratinocyte proliferation by regulating cell cycle and augmenting IFN-1\u2212Induced jak1\u2212Signal transducer and activator of transcription 1 phosphorylation in psoriasis","volume":"142","author":"Huang","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1920111","DOI":"10.1155\/2021\/1920111","article-title":"Identification of latent diagnostic biomarkers and biological pathways in dermatomyositis based on WGCNA","volume":"2021","author":"Ouyang","year":"2021","journal-title":"J Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-021-02454-2","article-title":"Pharmacogenetic predictors of response to interferon beta therapy in multiple sclerosis","volume":"58","author":"Carrasco-Campos","year":"2021","journal-title":"Mol Neurobiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05469-5","article-title":"Genetic predisposition in the 2'-5'A pathway in the development of type 1 diabetes: potential contribution to dysregulation of innate antiviral immunity","volume":"64","author":"Pedersen","year":"2021","journal-title":"Diabetologia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"147032","DOI":"10.1016\/j.gene.2022.147032","article-title":"Construction of a novel immune-related prognostic-predicting model of gastric cancer","volume":"852","author":"Pang","year":"2023","journal-title":"Gene"},{"key":"B41","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/s12885-020-07034-6","article-title":"Prognostic characterization of OAS1\/OAS2\/OAS3\/OASL in breast cancer","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4804694","DOI":"10.1155\/2021\/4804694","article-title":"Integrative analysis of differently expressed genes reveals a 17-gene prognosis signature for endometrial carcinoma","volume":"2021","author":"Wang","year":"2021","journal-title":"BioMed Res Int"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1186\/s12885-022-10102-8","article-title":"Values of OAS gene family in the expression signature, immune cell infiltration and prognosis of human bladder cancer","volume":"22","author":"Gao","year":"2022","journal-title":"BMC cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133123","article-title":"Single B cell gene co-expression networks implicated in prognosis, proliferation, and therapeutic responses in non-small cell lung cancer bulk tumors","volume":"14","author":"Ye","year":"2022","journal-title":"Cancers"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1011390","article-title":"Immune-related gene risk score predicting the effect of immunotherapy and prognosis in bladder cancer patients","volume":"13","author":"Zou","year":"2022","journal-title":"Front Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26219","article-title":"2'-5' oligoadenylate synthetase 1 polymorphism is associated with prostate cancer","volume":"117","author":"Mandal","year":"2011","journal-title":"Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"B51","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkab851","article-title":"OncoSplicing: an updated database for clinically relevant alternative splicing in 33 human cancers","volume":"50","author":"Zhang","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: multi-omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-0689","article-title":"TIP: A web server for resolving tumor immunophenotype profiling","volume":"78","author":"Xu","year":"2018","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac558","article-title":"GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels","volume":"24","author":"Liu","year":"2023","journal-title":"Brief Bioinform"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa1020","article-title":"TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment","volume":"49","author":"Sun","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00382-1","article-title":"The status of tumor mutational burden and immunotherapy","volume":"3","author":"Anagnostou","year":"2022","journal-title":"Nat Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019101573","article-title":"Suppressing PARylation by 2',5'-oligoadenylate synthetase 1 inhibits DNA damage-induced cell death","volume":"39","author":"Kondratova","year":"2020","journal-title":"EMBO J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.71385","article-title":"Establishment and validation of an interferon-stimulated genes (ISGs) prognostic signature in pan-cancer patients: A multicenter, real-world study","volume":"18","author":"Zhou","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"20438","DOI":"10.1038\/s41598-021-99736-5","article-title":"DLEU1 promotes oral squamous cell carcinoma progression by activating interferon-stimulated genes","volume":"11","author":"Hatanaka","year":"2021","journal-title":"Sci Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2551","article-title":"Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer","volume":"24","author":"Post","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363984","article-title":"Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR","volume":"4","author":"Knapp","year":"2003","journal-title":"Genes Immun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12967-023-03943-9","article-title":"Bioinformatics analyses of combined databases identify shared differentially expressed genes in cancer and autoimmune disease","volume":"21","author":"Sui","year":"2023","journal-title":"J Trans Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2013elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.03.031","article-title":"Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling","volume":"165","author":"Minn","year":"2016","journal-title":"Cell"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S187280","article-title":"Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-gamma-associated JAK-STAT pathway","volume":"12","author":"Xue","year":"2019","journal-title":"OncoTargets Ther"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2015.04.005","article-title":"Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection","volume":"17","author":"Ng","year":"2015","journal-title":"Cell Host Microbe"},{"key":"B77","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s43018-022-00490-y","article-title":"Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction","volume":"4","author":"Qiu","year":"2023","journal-title":"Nat Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","article-title":"Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade","volume":"178","author":"Benci","year":"2019","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-319-67577-0_3","article-title":"Regulation of CTL infiltration within the tumor microenvironment","volume":"1036","author":"Church","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3205","article-title":"Interferon-gamma regulates cellular metabolism and mRNA translation to potentiate macrophage activation","volume":"16","author":"Su","year":"2015","journal-title":"Nat Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00609-0","article-title":"Type I interferon signaling and macrophages: a double-edged sword","volume":"19","author":"Adler","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: an accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J BioMed Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1249731\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T02:24:04Z","timestamp":1697768644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1249731\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":84,"alternative-id":["10.3389\/fimmu.2023.1249731"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1249731","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]},"article-number":"1249731"}}